Would sure be nice to see insiders buying commons for a change. Given that real news may not happen for a while it would be a confidence boost to see some cash buys in addition to the thousands of options handed out recently.

Meaning at .20 you can get 5 shares for $1

Negative. There's no buyers so I'll be keeping an eye on it and when it finally starts to show an uptrend I may grab a few more. Wasn't going to get caught chasing this down the mountain.

A 5 for 1 deal coming soon to those that have been chasing this down since $1...all the way screaming it will never touch .80, .70, .60, .50, .40, .30., .20.

Well that's a whole lot of "potentiallys". The rare cannabinoid could potentially be huge. This rare cannabinoid's value could potentially be 10X something. They could potentially be signing contracts. They could potentially have a real down-stream partner. They could potentially not run out of cash. The yeasties could potentially have an inferior platform.
They could also potentially have the keys to the kingdom. The market however is clearly not investing in your potentiallys. It isn't even investing in your future potentiallys based on warrant pricing. The bears own this one for now. The only current fact that I see is that the share price is near its 52 wk low which is already in the .20s so keep on buying.

Not really a good comparison eh? Many in this sector are in near-term pullbacks after experiencing long periods of growth. Can you say that?

Warrants fell another 10% this morning. The market is reacting as if it has no confidence that they will meet their stated timelines?

He's a technical recruiter. Does that warrant a red carpet roll-out on wall street? Think not.

He is very emotional. Based on his conjecture this is likely his first trade.

The broader market is treating them as it should. Show me the goods and I'll reward you. Shower me with maybes and I'll wait patiently on the sidelines.

FB just starving for a Swanson report right about now

The major InMed warrant holder Eight Capital was gifted these warrants as part of the bought deal offering to raise cash last June. They're currently sitting on 14,444,560 common shares and 14,444,560 warrants. This is the majority of the batch set to expire in '20 and be dam* sure Eight Capital doesn't want to see their large pile of warrants expire worthless.

Why would any retail investor be buying risky warrants at this time? An irresponsible strategy. Commons are trading in the low .30s and could test .20s how freaking cheap do you want shares to even consider warrants?

Teewinot just hired some industry heavies and from the looks of it they're working on a transition plan from privately owned to publicly listed. One to watch in this space.

https://www.globenewswire.com/news-release/2019/05/22/1840742/0/en/Teewinot-Life-Sciences-Announces-Executive-Leadership-Changes.html

Similar boat Ricky. Regarding media until Josh was hired they had no social media presence. They're trying to be more "connected" via the social platforms, yet the trend is to push puff pieces in advance of investor conferences. I'm almost convinced that outside of insider ownership most of the shares being held are from w/in the FB group. Thing is that most of this group still can't grasp the unique qualities of plant biology and why many from industry are knocking e coli. It's not because they are using another platform or are too far behind to take that approach it's because there's a lot of data stating its limitations in this area. I've recently read most of the arguments during last weeks threads and many just aren't grasping it.

FB Glee Club. That's funny. Honestly this company has major potential, but don't expect much for another 1.5-2 yrs. If you're looking at near-term plays head elsewhere. This is a very high risk high reward play that may some day pay off big or fail like most other small biotechs.

Noted, but I think the results have been rather mixed. How are you personally quantifying "they're doing pretty good to be this far along"? Far along in what aspects? At this stage they are not on a Fast Track path, nor even planning an FDA filing in parallel to an HC filing. Both EB PH 1 and biosynthetics have been delayed. Some key leadership have left while others have joined. NRC grant was encouraging and understanding the CMO partner/s would be rather telling. There has been some research performed on the limitations of using escherichia coli for cannabinoid scaling. Most others are using yeast (bakers or other) or sugar for this process. Not enough people in the retail investment community can say w/any certainty that InMed has the bulletproof model.

Underlying issue here is the track record of missing milestones and repeated changes in corporate strategy. Look at the drug pipeline from only 2015. EB was 3rd in line to both ocular and pain. Now EB is the primary candidate. Most drug development companies would never have such a radical shift during preclinicals. You're either working towards a ground breaking drug (formulation + target disease) or you're not. They are still finalizing the EB formulation for christ's sake in the same year they expect to file. Already missed earlier EB targets and now w/biosynthesis slipping it's a cascade of missed milestones. Many better near-term plays in this sector as this is a long term hold w/real risk.

https://seekingalpha.com/instablog/27523743-point-of-return/3789506-all-natural-the-opportunity-in-pharmaceutical-cannabinoid-medicine-with-inmed-pharmaceuticals-inc

The 26% haircut to the warrants are rather indicative of no major news to be expected in the near-term

The FB page is turning into an echo chamber of baseless pumping. Almost laughable to read back over all of the irresponsible share price predictions over the past year. Some even going as far as trying to compare IMLFF to GW Pharma. IMLFF is a micro cap that is nothing more today than the lint in GW's pockets. GW has had a war chest of IP for years and IMLFF doesn't even have one patent. Have been long for quite a few yrs and have watched their strategic vision change on many occasions. Just look at a corporate presentation from '15 compared to today. I just cautious those to temper their expectations until something is proven. Too many folks willing to just walk off the ledge with their Master Tim.

I don't like Dr. Hossain's transition to an advisory role, however I'm not terribly concerned given that all indications are that the pieces are in place to complete formulation and scaling for biosynthesis. I'm here specifically for this....not INM-750. Will be watching the next couple of mos with cautious optimism.

Dr. Hossain is peeling back hours to devote to his other project Entourage Biosciences.

https://vimeo.com/304255784

It works Flair. You just need a full account to unlock the article, but it opens to Readers Digest "Treat Glaucoma While You Sleep" with a blurb about what the scientists at UBC (of course in conjunction w/our friends at IN) are doing with hydrogels.

Saw this as well. I believe the short-term allocation of 5.72 was earmarked for biosyn scale up costs in addition to new costs associated w/FDA and Health Canada prep in advance of INM-750 filings.

NickDiaz209 your previous comment was lost on most but well played. Subtle humor can be quite effective.

Not sure what you're looking at green, but I'm seeing a 30k and 40k block on the bid size right now at .49 and .50

Sure, any endorsement is encouraging. That said, does anyone really know the NSERC? Is this a reputable organization? Do we just assume this is something significant? I mean in all honesty $100k US is a drop in the bucket and would barely cover R&D expenses for a few weeks.

I've done a little DD sine seeing the article. Angel Publishing, who is responsible for the recent pump piece, is ran out of a small office space near me in Baltimore. A Kyle Renfrow is the apparent founder and he has no Wall Street or bona fide investment resume to speak of. You cannot find any information from Angel Publishing on who the resident expert is on their stock picks to justify a $2000 paid subscription. Doubt it has significant readership given the no name at the helm and the market reaction thus far from it.

The bought deal increase from $10 to $15 mil in itself is very significant. Smart money wants in and I feel almost certain that this new injection of funds will be tied to finalizing down-stream biosynthesis manufacturing. They were finalizing both bio-fermentation and purification plans/partners. The question is will these elements be performed via a partnership or is there a chance that the new monies will be spent on keeping this process, or part of it, fully in-house? Either way, all positive from how I see it.

Fairly certain I answered your question on the other board Stephen :)

My understanding was that TSX compliance once added to the exchange is based on a 2 year management plan demonstrating a reasonable likelihood of revenue within 24 months....this is for companies with no revenue. I am not sure if SP is also tied to this or not during that 24 mo period.

Per the LD Micro presentation InMed had $10.7 mil in cash on hand as of the end of March. IMO, another raise of $13 mil would exceed the required amount needed for continuation of pre-clinical trial preparedness. This new bought deal screams downstream bio-fermentation and purification infrastructure and scale up.

Of course there's always profit taking. The whole sector is green today as enthusiasm for the C-45 vote tomorrow. The question is will it hold this time, continue to rise up on expected news, or fall back into the 70's.

Here we go again. Up 12% in real-time. Let's see how things hold up through the C-45 vote tomorrow.

Someone may be getting some cannabinoid based business.

https://www.newcannabisventures.com/organigram-considering-10-million-investment-in-cannabinoid-biosynthesis-technology-developer-hyasynth/

Loving the uptrend today and volume. Hoping this is the start of a new run up to a piece of news that we've been patiently waiting for. I would personally love to see an update on biosynthesis.

Thanks for the tip nsomniyak. I'll keep that in mind. Who doesn't love a good happy hour...

Les (and others), my apologies as I do not have a subscription acct with IH that gives me outgoing PM access. I just saw that I have a mailbox and you amongst a few others had sent me PMs that I just bumped into this morning. Yours was from 24 Apr.

Shake, I communicated directly with the lead researcher on the study and I've shared this intel with some of the other IMLFF longs. His message was extremely bullish.

The research team at the University of British Columbia that participated with InMed on the nanoparticle hydrogel study think InMed is embarking on something very special

In regards to the variations in production costs, my understanding is that plant extraction is exorbitantly costly due to the high quantities required of the dried plant. What exactly those extraction costs are I am not sure for either THC or CBD. I also understand plant extraction to produce inconsistent and irregular results with wide variations in the quality of the extracted oils. Now in contrast while the start up costs for biosynthesis production is also quite high, the long-term residual costs are significantly lower once the bacterial/biosynthesis line is stood up and in production due to no longer requiring additional bulk dried cannabis. Biosynthesis extraction should not only result in significantly lower costs per gram to produce, but they will also be much more precise and able to target a much larger set of targeted cannabinoids.

Bought another 3000 at .69. I haven't lost faith and taking the opportunity to accumulate while the whole sector is having a major correction.